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Department of Medicine, University of Calgary and Libin Cardiovascular Institute, Calgary, Alberta, CanadaABSTRACT
b-adrenergic blocking agents, a pharmacologically diverse class of
cardiovascular medications, are recommended as ﬁrst-line treatment
for patients with hypertension and concomitant structural heart dis-
ease, and for angina and heart failure. Many within-class differences
exist, from pharmacokinetics and pharmacodynamics to ancillary ef-
fects, such as intrinsic sympathomimetic activity, antiarrhythmic ac-
tivity, a-1 adrenergic receptor blockade afﬁnity, and direct vasodilation.
Nebivolol is a third-generation, b1 selective, long acting b-blocker,
which causes direct vasodilation via endothelium-dependent nitric ox-
ide stimulation. The vasodilatory actions of nebivolol might result in
clinical effects with some distinct properties. Differences from other
b-blockers might include improvement of endothelial function,
enhancement of forward ﬂow in muscular resistance arteries, main-
tenance of exercise tolerance, and overall improved tolerability, side
effect proﬁle, and adherence. Nebivolol has been shown to be a clin-
ically effective b-blocker for treatment as initial or add-on therapy for
systemic hypertension, as an antianginal agent, and as therapy for
patients with heart failure. These properties position nebivolol as a
treatment option for patients with hypertension and/or structural heart
disease, although its precise role in the therapeutic armamentarium
remains to be clariﬁed.Received for publication October 5, 2013. Accepted March 3, 2014.
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ORESUME
Les inhibiteurs de b-adrenergiques, une classe pharmacologiquement
differente des medicaments pour le traitement des maladies car-
diovasculaires, sont recommandes comme traitement de première
intention chez les patients souffrant d’hypertension arterielle et de
cardiopathie structurelle concomitante, et contre l’angine et l’insufﬁs-
ance cardiaque. Il existe de nombreuses differences au sein de la
classe, allant des effets pharmacocinetiques et pharmacodynamiques
aux effets secondaires, comme l’activite sympathomimetique intrin-
sèque, l’activite antiarythmique, l’afﬁnite du bloquant pour les
recepteurs adrenergiques a-1 et la vasodilation par action directe. Le
nebivolol est un b-bloqueur b1selectif à action prolongee de troisième
generation qui cause une vasodilation à action directe par la stimu-
lation endothelium-dependante de l’oxyde nitrique. Les actions vaso-
dilatatrices du nebivolol pourraient entraîner des effets cliniques avec
certaines proprietes distinctes. Les differences par rapport aux
autres b-bloqueurs pourraient inclure l’amelioration de la fonction
endothelial, l’augmentation du debit en aval dans les artères de
resistance musculaire, le maintien de la tolerance à l’effort et
l’amelioration globale de la tolerabilite, le proﬁl des effets secondaires
et l’observance. Le nebivolol s’est avere un b-bloqueur cliniquement
efﬁcace en traitement initial ou complementaire de l’hypertension
systemique, comme antiangineux et pour traiter les patients souffrant
d’insufﬁsance cardiaque. Ces proprietes placent le nebivolol comme
une option de traitement des patients souffrant d’hypertension ou de
cardiopathie structurelle, ou les deux, bien que son rôle precis dans
l’arsenal therapeutique doit être clariﬁe.All b-adrenergic blocking agents (b-blockers) in clinical use
possess the ability to block the b1-adrenergic receptor to
various degrees.1 However, there is a high degree of within-
class heterogeneity.1 Some differences include b2-adrenergic
receptor afﬁnities, a1-adrenergic receptor antagonism, the
presence of intrinsic sympathomimetic activity, and directantiarrhythmic effects (eg, class III antiarrhythmic action).1,2
In addition to these differences, there are wide variations in
pharmacokinetics, pharmacodynamics, and ability to cross the
blood-brain barrier. Many of these issues are discussed in
detail elsewhere in this supplement to the Canadian Journal of
Cardiology. This review will focus primarily on one charac-
teristic of nebivolol: promotion of vasodilation via production
of nitric oxide.1,2 This property of vasodilation is shared by a
small number of other b-blockers, such as labetalol and car-
vedilol, although these 2 agents act via inhibition of the a1
postsynaptic adrenergic receptor.3 In this article we discuss
this aspect of nebivolol and how it might alter clinical effects
in relation to other b-blockers in 3 distinct cardiovascular
conditions: systemic hypertension, chronic angina, and heart
failure (HF).pen access under CC BY-NC-ND license.
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Brieﬂy, nebivolol is a third-generation b-blocker with
vasodilator properties.1,4 Nebivolol is the most b1-selective
blocker available, with a relative afﬁnity for b1/b2 receptors
>300.2 In addition, this hydrophilic drug possesses a long
half-life and a trough to peak ratio of 90%, a property shared
by few other b-blockers.5
Unlike 2 other vasodilating b-blockers, which block a1
receptors (carvedilol and labetalol), nebivolol possesses a direct
stimulatory effect on endothelial nitric oxide synthase
(eNOS), which results in increased levels of local nitric ox-
ide.1,5 In addition, there is evidence that nebivolol exerts an
antioxidant effect, which might produce additional vaso-
dilatory actions.2,6 Nebivolol is supplied in racemic form with
a 1:1 mixture of the d- and l-isomers.4,5 The d-isomer conveys
the b1-blocking effects and the l-isomer is primarily respon-
sible for eNOS stimulation.4,5
Under normal circumstances, the bulk of nitric oxide syn-
thesis in endothelium is thought to occur as a result of
endothelium-dependent generation through eNOS.7 Nitric
oxide plays a major and deﬁning role in vascular function.
Nitric oxide generation by the endothelium results in vasodi-
lation, reduced expression of proadhesion and inﬂammatory
receptors on the endothelial wall, and suppression of proin-
ﬂammatory secondary signalling.6,7 For these reasons, inade-
quate nitric oxide generation by the endothelium is thought to
represent the earliest form of endothelial dysfunction, predat-
ing any morphologic changes in diseased arteries.7,8 Thus, at-
tempts to determine the cardiovascular effects of interventions
focus on measurement of endothelial-dependent nitric oxide
generation and vasodilation through nitric oxide-dependent
pathways. In an ex vivo study, the direct vasodilatory effect
of nebivolol was abolished on removal of the endothelium in
the preparation.9 This effect was inhibited through adminis-
tration of N-mono-methyl-L-arginine (L-NMMA), a speciﬁc
inhibitor of eNOS. The precise manner in which nebivolol
enhances eNOS activity is not certain, but is likely to be due
either to binding of a metabolite to the b3 receptor (known to
cause vasodilation) or by directly enhancing endothelial aden-
osine triphosphate efﬂux via purinergic G protein inhibitory
receptors (preferentially stimulated by adenosine triphos-
phate).2,6,10 Nebivolol reduces expression of proadhesion and
inﬂammatory molecules on the endothelial wall and reduces
apoptosis and measures of oxidative stress.11 These effects have
been shown in several different animal and human models and
might contribute to vasodilatory effects in clinical practice.12 In
addition, stimulation of this pathway has been shown to
ameliorate ischemia-reperfusion myocardial injury13 and to
reduce end organ damage to the kidneys.14 Finally, application
of nebivolol to graft conduits for potential coronary bypass in
ex vivo preparations caused increased nitric oxide generation,
unlike atenolol.15
There is evidence supporting the clinical relevance of these
properties of nebivolol. For example, administration of nebi-
volol to healthy volunteers decreased heart rate, systemic
blood pressure (BP), and systemic vascular resistance, but not
left ventricular (LV) ejection fraction (LVEF).2 These are not
typical effects of early b-blocker administration. Van Bortel
and van Baak, in another study, compared exercise tolerance
in healthy volunteers given nebivolol 5 mg vs atenolol 100 mg
daily.16 In this small study, both drugs decreased BP to asimilar degree, although atenolol decreased peak exercise heart
rate more than nebivolol. Atenolol also reduced peak exercise
and endurance, whereas nebivolol was not associated with any
change in peak exercise, endurance, or perceived exercise
effort. The dose of atenolol was proportionately greater in
terms of b-blockade than nebivolol in this study, a design
feature favouring nebivolol (see Table 1). Other studies, such
as that by Van Nueten et al., used a more appropriate
comparator dose of atenolol to nebivolol: 50 mg atenolol vs 5
mg nebivolol. In this study, 365 patients with essential hy-
pertension were randomized to once-daily doses of nebivolol 5
mg, atenolol 50 mg, or placebo for 4 weeks. At the end of the
study, similar reductions in systolic and diastolic BP and in
heart rate (8 beats/min) were observed.22
Nebivolol increases forearm blood ﬂow with exercise
without changing baseline blood ﬂow.23 This feature is pre-
served with exercise at high altitude,24 and is not shared
with carvedilol, even though the latter does possess a weak,
a1-adrenergic receptor blocking effect, perhaps because the
latter effect might not be maintained after months of therapy.25Effects on Endothelial Function, LV Mass
Regression, and BP Control
Endothelial dysfunction is well known to exist in systemic
hypertension.8 Although attenuation of uncontrolled hyper-
tension will lead to improvement in endothelial function, not
all antihypertensive agents are associated with improvement
in this parameter.8 Tzemos et al. evaluated the effects of a
nebivolol/bendroﬂuazide (5/2.5 mg) combination with that
of atenolol/bendroﬂuazide (50/2.5) on endothelial function
using forearm venous occlusion plethysmography.26 An
infusion of acetylcholine was used to assess stimulated nitric
oxide release and L-NMMA was used to measure basal nitric
oxide release, and nitroprusside infusion for endothelium-
independent vasodilation. The study used a randomized,
crossover design. Baseline BP was 154/97 mm Hg in the
group of 12 patients. After 8 weeks of treatment, and despite
similar reduction in BP, the nebivolol but not the atenolol
group had an improvement of the vasodilatory response to
acetylcholine and attenuated the vasoconstrictive response to
L-NMMA. There was no difference between the 2 groups
with nitroprusside infusion, which suggested that nebivolol
but not atenolol improved endothelial function in this group.
In another study, Simova et al. compared endothelial func-
tion in 20 hypertensive patients via ﬂow-mediated dilatation
(FMD). They found that in a crossover design, treatment
with nebivolol increased FMD from 4% to 8% (P < 0.001)
and bisoprolol treatment did not change FMD from the
baseline of 3.8%.27
The Losartan Intervention For Endpoint (LIFE) trial
showed that the angiotensin-II receptor inhibitor losartan is
superior to atenolol for reduction of morbidity and mortality
in patients with hypertension and LV hypertrophy (LVH).28
One frequently reported ﬁnding of this study suggested that
antihypertensive agents active on the renin-angiotensin system
are more potent in reducing LVH than b-blockers. However,
in 2011, Caglar and Dincer reported data from a group of 106
patients with uncontrolled hypertension and LVH, who
received 5 mg nebivolol or 2.5 mg ramipril daily in a ran-
domized, open-label design.29 During the course of the
Table 1. Summary of comparative studies on exercise tolerance and other measures: nebivolol vs other b-blockers
Lead author Comparator Study design Study size (n) Results Comments
Gunes, 200917 Placebo vs nebivolol 5 mg;
duration, 12 weeks
Randomized, blinded,
parallel in patients with
angina or positive
treadmill test
54 patients (27 nebivolol,
27 placebo)
Nebivolol improved
diastolic function
parameters, exercise
time, and angina
Kayaalti,
201018
Placebo vs nebivolol 5 mg;
duration, 4 weeks
Randomized blinded,
parallel study in patients
with syndrome X
38 Patients (20 nebivolol,
18 placebo)
Nebivolol improved
brachial artery diameter
and levels of hsCRP,
vWF, and ﬁbrinogen
Ruf, 199419 Atenolol 100 mg vs
nebivolol 5 mg;
duration, 6 days
Randomized, double blind,
parallel study in patients
with angina
24 patients, 12 with each
therapy
Similar improvement in
exercise time and time to
ST segment depression
Early similar effect after
dosing; effect of atenolol
but not nebivolol waned
at end of dosing interval
Sen, 200920 Metoprolol 50 mg vs
nebivolol 5 mg, and
control; duration,
12 weeks
Randomized, double blind
parallel study in patients
with syndrome X
54 patients, 19 in each
active group, and 16
control subjects
Superior improvement in
exercise duration and
time to ST segment
depression in nebivolol
group; 70% of patients
in teh nebivolol group
improved by 1 or more
CCS class, vs 41% in the
metoprolol group
(P < 0.05)
Tepliakov,
200521
Metoprolol CR 50 mg vs
5 mg nebivolol
Randomized, blinded
parallel trial in patients
with angina after
myocardial infarction
40 patients, 20 in each
group
Both medications reduced
angina attack frequency
and exercise time and
nitroglycerine use
Nebivolol also reduced
serum triglycerides; no
change with metoprolol
Van Bortel,
199216
Atenolol 100 mg vs
nebivolol 5 mg vs
placebo; duration,
6 weeks
Randomized, double blind
crossover design in
healthy volunteers
21 Patients Greater reduction of heart
rate at rest and activity
and reduced exercise
capacity with atenolol
compared with nebivolol
This study was conducted
in healthy volunteers
who were not
hypertensive so ﬁndings
might not apply to those
with coronary disease
CCS, Canadian Cardiovascular Society; hsCRP, high-sensitivity C-reactive protein; vWF, von Willebrand factor.
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Cardiovascular Effects of Nebivolol39-week study, a thiazide diuretic was added to the drug
regimen in 97% of the ramipril subjects and 92% of those
taking nebivolol to achieve normotension. In both groups, BP
(measured by unblinded personnel) was reduced to similar
degree: ramipril reduced systolic BP 32 mm Hg compared
with placebo, and ramipril reduced systolic BP 33 mm Hg. At
39 weeks, the ramipril group experienced a reduction in LVM
index by 14.8 g/m2 (P < 0.001) and the nebivolol group
experienced a much greater reduction in LVM by 31.9 g/m2
(P < 0.001). The 17.1 g/m2 difference between the 2 was
statistically signiﬁcant (P < 0.001). In another study by
Fountoulaki et al., 40 controlled hypertensive patients with
LVH according to 2-dimensional echocardiography were
randomized to either 2.5-5 nebivolol (treated to control BP)
or 40-80 mg telmisartan.30 No additional drugs were added
during the course of the trial. In this study, both groups
demonstrated a similar decrease in BP, and a 14 g/m2 decrease
in LVM. In another study, carvedilol, another vasodilating
b-blocker,31,32 and nebivolol similarly reduced LVM in pa-
tients with LVH. In somewhat of a contrast to these data,
Galzerano and colleagues reported a superior effect of telmi-
sartan 80 mg compared with carvedilol 25 mg twice per day
(bid), on LVM regression in 82 hypertensive patients with
LVH followed for 44 weeks.33 In this study, the LVM
regression from telmisartan was 15% vs 9% with carvedilol (P
< 0.01). Thus, the ability of nebivolol to induce LVH
regression compared with other highly effective drugs, such as
angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers, is unclear, but might be equivalent.The LIFE investigators postulated that losartan was supe-
rior to atenolol in reduction of LVH and cardiovascular
outcomes because of differences in central, rather than pe-
ripheral, BP.34,35 Studies have suggested that b-blocking
agents with vasodilating properties might decrease central BP
more effectively than b-blockers without this property (while
exerting a similar effect on the peripheral BP).
Mahmud and Feely randomized 40 subjects with untreated
hypertension to either nebivolol 5mg/d or atenolol 50mg/d for 4
weeks.36 In this study, using aplanation tonometry with a pro-
prietary system (Sphygmocor system), the authors found that
aortic pulse pressure ampliﬁcation by augmentation index,
decreased with nebivolol (from 10 to 7 mm Hg) and it increased
with atenolol, from 8 to 14. These data are consistent with the
hypothesis that b-blockers might vary in their effects on central
aortic pressure. Koumaras et al. assessed the effects of 4 drugs
(quinapril, aliskiren, atenolol, and nebivolol) on a variety of he-
modynamic measures in 72 patients with hypertension. After
treatment for 10 weeks, all agents decreased peripheral BP to a
similar degree, however, only atenolol failed to decrease the central
aortic pulse pressure.37 Pulse pressure ampliﬁcation is ameasure of
peripheral pulse wave reﬂection and is related to small muscular
artery function. These ﬁndings are consistent with a stimulatory
effect on eNOS production in these arteries, which results in
increased peripheral blood ﬂow during exercise.20,23 The reduc-
tion of peripheral arterial resistance might also secondarily
improve central myocardial pressures during systole and diastole.
Vinereanu and colleagues used a Parallel, Randomized,
Open-Label, Blinded Endpoint (PROBE) study design to
S32 Canadian Journal of Cardiology
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echocardiography) of a 6-month course of either nebivolol or
short-acting metoprolol in 60 patients.38 Although systolic
and diastolic BP decreased in a similar fashion with both
medications, greater improvement in early diastolic ﬁlling
velocity (E wave), longitudinal displacement (longitudinal LV
strain), and LV ejection fraction (5%; P < 0.05) were all
observed with nebivolol but not the short-acting metoprolol.
In terms of efﬁcacy, several randomized, blinded, placebo-
controlled studies have been reported. Although a full
assessment of the antihypertensive efﬁcacy of nebivolol is
included elsewhere in this supplement to the Canadian
Journal of Cardiology, we will brieﬂy overview a few studies.
Lacourciere et al. showed in 1994 that over 24 hours, BP
reduction in 29 hypertensive patients with nebivolol (up to 10
mg/d) was similar to treatment with lisinopril (40 mg/d).39 In
an 8-week randomized crossover study, nebivolol and lisino-
pril produced similar decreases in mean 24-hour BP (14.8 
11.4 mm Hg for nebivolol vs lisinopril 17.9  12.2; P ¼
0.49). These and other studies suggest nebivolol to be
approximately equivalent in antihypertensive efﬁcacy to the
other agents tested.22,28,39-48 To date, the most comprehen-
sive meta-analysis of nebivolol compared with other treat-
ments was reported by Van Bortel et al. in a 2008
compendium of 12 studies, ﬁnding a similar rate of treatment
response and BP normalization as other antihypertensive
agents.40
These data suggest that nebivolol is an efﬁcacious treat-
ment for hypertension, with data supporting an improvement
of endothelial function, enhanced markers of peripheral blood
ﬂow, and improvement in LV structure and function.Effects on Coronary Flow and Control of
Myocardial Ischemia
The bulk of available evidence supports the vasodilatory
effect of nebivolol on coronary arteries in normal men,16
although case reports of more typical b-blocker-induced
spasm have been reported.49 Improved coronary sinus and left
anterior descending blood ﬂow and improvement in regional
LV systolic function in humans and animal models with
coronary artery disease and/or abnormal coronary blood ﬂow
were reported by Gunes et al. and others (see
Table 1).6,17,50-52 Improvement of endothelial function in
patients with syndrome X who were given nebivolol have also
been shown.12,18,20,53 Differences in coronary ﬂow reserve
between nebivolol and atenolol, measured using transthoracic
Doppler ﬂow velocity, were shown in 63 patients with hy-
pertensive heart disease by Gullu et al.54 The measured cor-
onary ﬂow reserve increased in the nebivolol group (from 2.45
to 2.56; P ¼ 0.09), vs a reduction with atenolol (from 2.46 to
2.21; P ¼ 0.006).
In one small study, a 3-month course of nebivolol 5 mg
daily, was given to 20 treatment naive patients who were
newly diagnosed with hypertension.55 Doppler echocardiog-
raphy was used to measure LV ﬁlling indices and coronary
ﬂow in the left anterior descending artery. After a 3-month
treatment period, there was evidence of improved LV ﬁlling
pressure (measured according to E/E’ ratio) and coronary ﬂow
normalized for the rate-pressure product (heart rate  systolic
BP). The 2 variables changed in similar fashion, suggestingthat the increase in normalized coronary blood ﬂow might be
related to a decrease of LV ﬁlling pressures with treatment. In
a comparative study of anti-ischemic activity of nebivolol vs
atenolol, Ruf et al. studied 24 patients over 6 days of treat-
ment (see Table 1).19 Time to ischemia, total exercise time,
and ST segment depression at 3 hours after dose were similar
between the 2, however less ST-depression was observed in
the nebivolol group at the trough period (24 hours) compared
with that the atenolol group.
b-Blockers are considered initial therapy for treatment
of hypertension with concomitant coronary disease by the
Canadian Hypertension Education Program.56 Recent sup-
porting evidence can be found in a subanalysis of the Study
of the Effects of Nebivolol Intervention on Outcomes and
Rehospitalization in Seniors with heart failure (SENIORS)
trial, in which data on elderly patients with known coronary
artery disease were reviewed separately.57,58 As expected,
mean baseline systolic BP was only 141 mm Hg. In this
analysis, cardiac ischemic events occurred in 15.9% of
placebo-treated patients and 10.7% of nebivolol-treated pa-
tients (P ¼ 0.008), conﬁrming the anti-ischemic effect of
nebivolol. This evidence stands out because there is a paucity
of studies that have reported hard cardiovascular outcomes for
any drug of any class for treatment of angina. In comparison
with the long-acting metoprolol CR in 40 patients with LV
dysfunction after myocardial infarction, HF, and angina, both
medications signiﬁcantly reduced the number of angina at-
tacks by >73% and the frequency of angina (68%), and
increased exercise tolerance. No data were collected on the
change in LVEF (see Table 1).21
These data support the usefulness of nebivolol in patients
with coronary artery disease, with or without LV systolic
dysfunction.Effect on LV Function and HF
Early work with nebivolol in trials of patients with LV
dysfunction and HF revealed improvements in symptoms of
HF, lack of change in exercise tolerance, and improvements in
cardiac structure and function.59,60 In the Effects of the Long-
term Administration of Nebivolol on the Clinical Symptoms,
Exercise Capacity, and Left Ventricular Function of Patients
With Diastolic Dysfunction (ELANDD) study,61 Conraads
et al. randomized 116 subjects with HF and preserved ejection
fraction and New York Heart Association class II-III to 6
months of treatment with nebivolol or placebo in a double-
blind, parallel group design. In this study, no change in 6-
minute walk test, or quality of life scores were noted in the
nebivolol group, suggesting nebivolol was well tolerated, but
no clinical beneﬁt was noted. Nodari et al. compared the ef-
fects of nebivolol and atenolol on symptoms and hemody-
namics in patients with hypertension and diastolic HF.62 In
this study, both drugs decreased BP to a similar degree, but
nebivolol was associated with superior oxygen uptake and
anaerobic threshold, greater reduction of pulmonary artery
and LV ﬁlling pressures, and to better exercise duration and
less attenuation of LV stroke volume.
In another study, nebivolol, bisoprolol, and carvedilol were
given in a randomized crossover design in 61 patients with
hypertension and HF with reduced systolic function. Patients
were treated with each drug for 3 months.63 The mean
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noted in terms of symptoms, biochemical parameters, or
quality of life, however, bisoprolol and nebivolol were asso-
ciated with a slightly higher peak exercise capacity (15.8 for
carvedilol, 16.9 for nebivolol and bisoprolol). In addition,
carvedilol was associated with a lower diffusion capacity
compared with the other 2 drugs, suggesting impairment of
these functions, possibly because of b2-receptor inhibition.
Change in LVEF was not reported. In another study of HF
patients with low LVEF, carvedilol was associated with a
nonsigniﬁcant numerically larger increase in LVEF over
nebivolol, with LVEF increasing from 28% to 35% with
carvedilol vs 31% to 36% with nebivolol.64 Both drugs were
associated with improved New York Heart Association class,
quality of life, and diastolic parameters at 12 months of
follow-up. In a sister study, the same researchers reported
initial deterioration in exercise capacity with nebivolol in pa-
tients with nonischemic cardiomyopathy before improvement
at 12 months.65 In contrast, Lombardo et al. reported in 70
systolic HF patients that no differences in symptoms, exercise
time, improvement in LVEF, or premature ventricular beats
were seen with carvedilol (25 mg orally bid) vs nebivolol
(5 mg orally bid).66 Thus, although there is some evidence
that carvedilol might be superior to nebivolol for the man-
agement of systolic HF, it is clear that both drugs exert pos-
itive effects on the condition.
Nebivolol has also been tested for prevention of LV systolic
dysfunction. Kaya et al. reported the results of a randomized,
controlled trial of 45 consecutive patients who received
nebivolol 5 mg or placebo before anthracycline treatment.67
At baseline both groups has similarly normal LV volumes,
ejection fraction, and N-terminal-pro-brain natriuretic pep-
tide level. At 6 months, LVEF was greater in the nebivolol
than placebo group (64% vs 57%; P ¼ 0.01). Although in-
creases in LV end-systolic and end-diastolic volumes were
observed in the placebo group, no change was noted in the
nebivolol group. Similarly, N-terminal-pro-brain natriuretic
peptide levels increased in the placebo but not the nebivolol
group. As such, nebivolol might potentially be useful for
prevention of chemotherapy-induced LV dysfunction and
failure, although this has yet to be clinically proven.Outcomes in HF With b-Blocker Therapy
Three b-blockers are currently approved for treatment of
HF due to systolic dysfunction: carvedilol,68-70 bisoprolol,71
and the long-acting form of metoprolol succinate.72-75 All 3
were shown in randomized clinical trials to decrease the rate of
death by approximately 33%, irrespective of symptoms, and
to reduce cardiovascular hospitalizations, primarily due to HFTable 2. Comparison of key features of 5 major b-blocker trials for treatme
Study name Study size and mean follow-up
Average
age
Upper limit o
LVEF allowed,
CIBIS-II71 2647 patients-1.3 years follow up 61 years 35
MERIT-HF73 3991 patients-0.9 years follow up 64 years 40
COPERNICUS70 1289 patients-0.9 years follow up 63 years 25
SENIORS76 2128 patients-1.75 years follow up 76 years None
CIBIS-II, Cardiac Insufﬁciency Bisoprolol Study-II; COPERNICUS, Carvedilol
ventricular ejection fraction; MERIT-HF, Metoprolol CR/XL Randomized Interve
Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure.(see Table 2). The study of the effects of nebivolol interven-
tion on outcomes and rehospitalization in seniors with HF
(SENIORS study) was published in 2005.76 In this trial, 2128
subjects, all older than 70 years of age and suffering from
chronic HF, were randomized to receive nebivolol (target dose
of 10 mg once daily) or matching placebo. After nearly 1.8
years of follow up (nearly double that of other b-blocker HF
trials), the study demonstrated only a 14% reduction (95%
conﬁdence interval, 0.74-0.99) in the primary end point of
death plus any cardiovascular hospitalization. However, the
improvement occurred despite the inclusion of more than
20% of the cohort with HF due to preserved systolic function
(LVEF >40%), a condition in which no therapy has been able
to show pharmacologic improvement in clinical outcomes.
Because of heterogeneity of outcomes in different
b-blockers trials, such as with the negative outcome of
bucindolol in the Beta-Blocker Evaluation of Survival Trial
(BEST) trial,77 each b-blocker should be evaluated on its own
merits and the reduction of morbidity and mortality with b-
blockers for systolic HF should not be considered a class ef-
fect. This point is supported by the Carvedilol or Metoprolol
European Trial (COMET), in which carvedilol 25 mg bid was
compared with metoprolol tartrate up to 50 mg bid in pa-
tients with mild to moderate HF with an end point of total
mortality.57,77 In this large, 5000 patient, 5-year, randomized,
double-blind active control study, there was a highly signiﬁ-
cant 17% reduction of mortality in carvedilol-treated vs
metoprolol-treated patients, further underscoring the need to
use evidence-based b-blockers for HF.
It has been suggested that the SENIORS trial results were
not sufﬁciently positive to warrant inclusion of nebivolol into
the group of b-blockers considered effective for HF. The
14% reduction in morbidity and mortality produced by
nebivolol in SENIORS was less than that seen with carve-
dilol, metoprolol succinate (not the formulation bested by
carvedilol), or bisoprolol (see Table 2). However, the SE-
NIORS study enrolled patients who were on average 10 years
older than the in other trials, and included more than a third
of subjects with an LVEF >35%. This point is likely critical
because a large individual patient meta-analysis of more than
35 HF trials totaling over 90,000 patients showed that in
terms of baseline LVEF, mortality was not related at all to
ejection fraction until it decreased to <40%, at which point
it increased in linear fashion as LVEF decreased.78 This
suggests that at greater LVEFs, especially >40%, there might
be limited potential for b-blockers to reduce mortality.
Indeed, in a post hoc analysis in which only subjects younger
than the age of 75 (the median age was 76) years, and
depressed LVEF in the SENIORS trial were considered, the
hazard ratio for total mortality was much less at 0.72, whichnt of heart failure
f
%
Mean
LVEF, %
Percentage
of LVEF >35%
Placebo annualized
mortality, %
Percentage reduction
of CV mortality
28 0 13.2 29
27 6 11.0 38
20 0 19.7 35
34 36 10.4 16
Prospective Randomized Cumulative Survival; CV, cardiovascular; LVEF, left
ntion Trial in Heart Failure; SENIORS, Study of the Effects of Nebivolol
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Volume 30 2014is of the same order as that noted in the other 3 positive b-
blocker trials (with a combined total mortality reduction of
34%). Nevertheless, such post- hoc ﬁndings are only
hypothesis-generating at best.79
Data from the SENIORS echocardiography substudy are
consistent with a dichotomy of b-blocker effect at ejection
fractions > and <35%. In this small substudy, which
included only 104 patients from the SENIORS trial, study
subjects were divided into those with LVEF at baseline >35%
and <35%. The subjects underwent a variety of echocardio-
graphic measures at baseline and 6-month follow-up. In the
43 subjects with baseline ejection fraction <35%, there was
an improvement of ejection fraction by an average of 4.6%,
similar to changes seen with other b-blockers, with nebivolol
therapy. In contrast, the 61 subjects with a baseline ejection
fraction >35% did not show change in any echocardiographic
parameter. Thus, it is possible that the inclusion of patients
with preserved ejection fraction in the SENIORS trial served
to dilute the beneﬁt that otherwise might have been observed.
However, it must be noted that no treatment beneﬁt inter-
action with LVEF was observed in terms of the outcomes.80
Several authors have suggested that the results of the SE-
NIORS trial do not show similar beneﬁts comparable with
other HF b-blocker trials.81 The European Society of Cardi-
ology places nebivolol in the list of b-blockers acceptable for
use in HF, although the recommendation is qualiﬁed,
acknowledging the lack of a total mortality beneﬁt.74 In
contrast, the American Heart Association/American College of
Cardiology HF Guidelines do not recommend nebivolol for
chronic systolic HF.75 Nebivolol has not undergone review for
treatment of HF in Canada, and is therefore not so indicated
in Canada.Side Effect Proﬁle and Adherence
b-Blockers are associated with many potential side effects
including fatigue, dyspepsia, somnolence, decreased libido,
and erectile dysfunction.1,4,6,12 Consequently, drug discon-
tinuation rates, particularly for antihypertensive medications
(treatment for an asymptomatic condition) remain a problem.
Previous work has shown that some side effects of b-blockers
might be in part due to peripheral vasoconstriction or
decreased cardiac output.
Several randomized, placebo-controlled trials have evalu-
ated the efﬁcacy and tolerability of nebivolol. Some of these
trials suggest a very low incidence of side effects, comparable
with placebo,42 and a possibly more favourable proﬁle when
compared with other agents. In a meta-analysis of 12 ran-
domized controlled studies, nebivolol was shown to achieve
similar BP control, but with a side effect proﬁle similar to
placebo, and fewer side effects than losartan, calcium antag-
onists, other b-blockers, and other antihypertensive agents.40
In another meta-analysis of 10 trials (3 of which were
judged to be of high quality) comparing nebivolol with
atenolol, bisoprolol, or metoprolol, nebivolol also showed few
adverse events and drug withdrawals while exhibiting similar
efﬁcacy.82 Exclusion of the 7 lower-quality studies did not
change the overall ﬁndings. In addition, erectile dysfunction, a
side effect frequently attributed to b-blockers,83 occurred less
frequently with nebivolol compared with other b-blockers and
to a similar degree as losartan (23% nebivolol vs 28% withlosartan).46,83,84 In addition, Brixius et al. found that in 48
male hypertensive patients, 12 weeks of therapy with meto-
prolol worsened the International Index of Erectile Dysfunc-
tion Score, whereas 12 weeks of nebivolol signiﬁcantly
improved it.85 Finally, Boydak et al. directly compared
nebivolol, atenolol, and chlorthalidone in 131 male patients.
The group receiving nebivolol did not experience a reduction
in the monthly episodes of sexual intercourse (6.4 to 6.0 per
week at 3-month follow-up), unlike the groups receiving the
other 2 agents.86
The side effect proﬁle of nebivolol might directly affect
drug adherence, a key component of successful treatment of
hypertension.84 Several articles have noted differences in drug
adherence among classes of antihypertensive medications.
Mancia et al. reported on observational data from an
Italian cohort of >130,000 individuals.87 Drug discontinua-
tion was deﬁned by absence of the drug prescription for more
than a 90-day period after previous usage. In their analysis,
overall discontinuation rate was 6.2/100 person-months for
angiotensin-receptor blockers (n ¼ 34,438), and diuretic (n ¼
8871) discontinuation rates were reported as 24.4/100
person-months. For b-blockers (n ¼ 19,063), they reported
intermediate rates of 13.9/100 patient-years. Within each
class however, there were different rates of discontinuation.
Perhaps unsurprisingly, the b-blocker and calcium-blocker
classes exhibited the greatest heterogeneity in discontinua-
tion rates (from 4.5 to >50/100 person years). Within the b-
blocker class, nebivolol exhibited the lowest discontinuation
rate at just over 10/100 person years (2918 discontinued of
27,221 patient-years exposure).
Chen et al. presented observational data from a large
retrospective American claims database. In this study,
compliance with nebivolol (n ¼ 593) vs diuretic therapy as
ﬁrst prescription (n ¼ 17,321) was measured according to
medication processing ratio (total days of medication divided
by total study period). At 12 months, the medication pro-
cessing ratio for nebivolol was 0.76 vs 0.70 for the diuretic
class (P < 0.001).88Conclusions
Nebivolol is a third-generation, long acting, and highly b1-
selective b-blocking agent with direct vasodilatory properties
due to stimulation of eNOS activity in peripheral arteries.
Compared with commonly used nonvasodilating b-blockers
such as atenolol and metoprolol, nebivolol might provide
better control of central aortic BP and improved exercise
tolerance. A variety of evidence suggests potential superiority
in a number of clinically relevant areas related to tolerability
and efﬁcacy for certain indications; however, there are as yet
no hard data that conﬁrm such superiority. Its properties
suggest a role for nebivolol in the management of hyperten-
sion, or as an alternative b-blocker for treatment of angina or
HF. The precise role of nebivolol in the therapeutic arma-
mentarium remains to be deﬁned in future studies.Funding Sources
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